Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

D Rischin; NI Khushalani; CD Schmults; A Guminski; ALS Chang; KD Lewis; AM Lim; L Hernandez-Aya; BGM Hughes; D Schadendorf; A Hauschild; E Stankevich; J Booth; S Li; Z Chen; J Desai; I Lowy; MG Fury; MR Migden

Conference Proceedings

Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

D Rischin, NI Khushalani, CD Schmults, A Guminski, ALS Chang, KD Lewis, AM Lim, L Hernandez-Aya, BGM Hughes, D Schadendorf, A Hauschild, E Stankevich, J Booth, S Li, Z Chen, J Desai, I Lowy, MG Fury, MR Migden

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

DOI: 10.1093/annonc/mdz451.006

Abstract

Background Cemiplimab demonstrated antitumour activity and an acceptable safety profile in a phase II study of pts with CSCC (NCT02760498). Here, we report efficacy by PST. Methods The primary objective of the study is to evaluate the objective response rate (ORR) by independent central review (ICR). Pts with metastatic CSCC (mCSCC; Group 1) and locally advanced CSCC (Group 2) received 3 mg/kg Q2W for 96 weeks, and mCSCC received 350 mg Q3W for 54 weeks (Group 3). Data cutoff dates were 20 September 2018 (Groups 1 and 3) and 10 October 2018 (Group 2). Results Of the 193 pts enrolled, 128 had cemiplimab as first-line therapy (1LT) and 65 had PST (table). Median follow-up was 9.4 months. The O..

View full abstract